Singletary S E, Umbach G E, Spitzer G, Drewinko B, Tomasovic B, Ajani J, Hug V, Blumenschein G
Int J Cell Cloning. 1985 Mar;3(2):116-28. doi: 10.1002/stem.5530030205.
The human tumor stem cell assay (HTSCA) is a bilayer soft agar system for growing fresh human tumor specimens in vitro to determine drug sensitivity and improve our understanding of tumor biology. Recent clinical correlations of 60% accuracy for predicting a positive clinical response and a 90% accuracy for predicting a lack of response to therapeutic agents suggest promising clinical usefulness. However, the clinician should be aware of the assay's inherent pitfalls, such as heterogeneity of the tumor specimen, inability to obtain pure single-cell suspensions, low cloning efficiency, unusual drug dose-dependent survival curves, uncertain validity of in vitro pharmacology, non-standardized criteria for in vitro sensitivity, and the variability of in vitro results. A brief summary of the concepts, potential, and limitations of this assay are discussed.
人肿瘤干细胞检测（HTSCA）是一种双层软琼脂系统，用于在体外培养新鲜的人肿瘤标本，以确定药物敏感性并增进我们对肿瘤生物学的理解。最近，该检测在预测阳性临床反应方面有60%的准确率，在预测对治疗药物无反应方面有90%的准确率，这表明其具有良好的临床应用前景。然而，临床医生应意识到该检测存在的固有缺陷，如肿瘤标本的异质性、无法获得纯单细胞悬液、克隆效率低、异常的药物剂量依赖性存活曲线、体外药理学有效性不确定、体外敏感性标准不规范以及体外结果的变异性。本文讨论了该检测的概念、潜力和局限性的简要总结。
